In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres
| Autor: | BA Todd A. Scungio, BS Stephen P. Mayock, BS Michael P. Grima, Alison B. Fleming |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Chemistry
Pharmaceutical Pharmacology Dosage form Microsphere 03 medical and health sciences 0302 clinical medicine 030202 anesthesiology Medicine Humans Pharmacology (medical) Syringe business.industry Opioid abuse Temperature General Medicine Opioid-Related Disorders IV injection Microspheres Analgesics Opioid Anesthesiology and Pain Medicine Opioid Anesthesia Injections Intravenous business Oxycodone 030217 neurology & neurosurgery Intravenous route medicine.drug |
| Zdroj: | Journal of opioid management. 12(1) |
| ISSN: | 1551-7489 |
| Popis: | Objective: Abuse of prescription analgesics is a well-recognized problem, with nearly 2 million people aged 12 years or older initiating nonmedical use of pain relievers in 2012. The prevalence of opioid abuse via intravenous (IV) injection has led to the development of dosage forms designed to deter abuse using different inactive ingredients and formulation strategies. This study evaluated the IV abuse potential for a novel, microsphere-encapsulated abuse-deterrent formulation of oxycodone, Xtampza™ ER (referred to as “oxycodone DETERx”). Methods: The extraction of oxycodone DETERx and two comparators, extendedrelease oxycodone (oxycodone ER) and immediate-release oxycodone (oxycodone IR), was evaluated in small volumes (5 and 10 mL) of water after manipulation of the dosage forms. The syringeability and injectability of these products were evaluated to determine the feasibility of using these products via IV injection. Results: The extraction of oxycodone from oxycodone DETERx was nominal, with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|